Equities

GlaxoSmithKline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,946.60
  • Today's Change66.80 / 3.55%
  • Shares traded120.03k
  • 1 Year change+52.32%
  • Beta0.5286
Data delayed at least 15 minutes, as of Mar 28 2024 10:28 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. It has three product areas: vaccines, specialty and general medicines. Its general medicines business has a portfolio of medicines in anti-infectives, pain, dermatology and vitamins. Its general medicines brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact and Physiogel. Its T-bact brand products are used in specific types of bacterial skin infections. The Company's vaccine brands include Shingrix, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicines business is focused on developing medicines for respiratory diseases and human immunodeficiency virus. The Company is also building its presence in other therapeutic areas, such as immunology and oncology. Its specialty medicines brands include Nucala and Trelegy Ellipta.

  • Revenue in INR (TTM)33.11bn
  • Net income in INR5.29bn
  • Incorporated1924
  • Employees3.68k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Piramal Pharma Ltd77.82bn-333.40m161.25bn6.30k----23.182.07-0.3002-0.300263.15--------12,362,800.00--------64.29---0.4284----6.36----7.97---149.60------
Suven Pharmaceuticals Ltd11.68bn3.71bn162.91bn1.17k43.91--38.7913.9514.5814.5845.91--------10,023,860.00--------58.68--31.76----86.09----1.52---9.37------
Natco Pharma Ltd.38.28bn12.78bn174.36bn3.98k13.74--12.024.5570.8470.84212.24--------9,621,513.00--10.34--12.0478.2675.1133.3822.66--90.50--21.3439.204.22320.760.5428-19.11-8.34
Sanofi India Ltd28.51bn6.03bn183.34bn3.53k30.4118.0628.546.43261.78261.781,237.96440.801.512.2421.86--31.8422.4250.3530.2157.8855.6921.1521.030.897449.470.018458.182.920.573-2.859.64-10.3414.73
Piramal Enterprises Ltd79.98bn-20.16bn187.82bn12.22k------2.35-90.77-90.77339.88--------6,545,270.00--3.41--4.5147.2988.04-25.2126.30--0.2287--22.746.82-4.74528.3114.25-24.794.90
Pfizer Ltd22.19bn5.02bn192.34bn1.70k38.31--33.338.67109.76109.76485.08--------13,038,660.00--13.81--17.6363.0861.2122.6323.22--50.30--84.31-7.134.131.8611.62-8.7511.84
Alembic Pharmaceuticals Ltd61.18bn5.90bn193.57bn14.59k32.80--22.083.1630.0230.02311.22--------4,192,490.00--11.45--15.3971.1066.439.8013.65--10.21--25.266.5412.54-34.35-3.69-11.6114.87
Laurus Labs Ltd49.82bn1.88bn211.38bn5.75k112.84--37.124.243.483.4892.17--------8,659,934.00--11.78--19.7551.7348.414.0214.16--2.50--12.3722.3923.90-4.5236.3620.4231.95
J B Chemicals and Pharmaceuticals Ltd33.85bn5.14bn254.97bn5.10k50.34--39.627.5332.6332.63214.87--------6,643,323.00--15.37--18.1865.8360.2015.1915.49--15.00--31.7329.9117.366.3524.2683.8454.75
Glenmark Pharmaceuticals Ltd117.51bn-12.31bn271.59bn15.56k------2.31-43.61-25.22416.16--------7,553,779.00--4.65--6.4661.0860.78-9.726.46--1.10--10.17-5.864.94-118.02---10.274.56
Ajanta Pharma Ltd40.36bn7.36bn276.20bn7.71k37.66--31.756.8458.2458.24319.08--------5,233,334.00--16.13--19.5274.1674.0118.2319.22--100.64--15.9312.0211.92-17.504.64-7.86--
Syngene International Ltd35.66bn5.00bn285.31bn6.85k57.19--31.338.0012.4512.4588.72--------5,208,267.00--8.80--11.9571.3670.6814.0317.00--6.88----22.6117.5417.338.747.340.00
Gland Pharma Ltd49.12bn6.59bn299.86bn4.59k45.53--31.626.1039.9839.98298.11--------10,713,810.00--15.16--16.6960.5453.9713.4126.07--46.26--0.00-17.6417.43-35.5419.4621.24--
IPCA Laboratories Ltd71.86bn5.64bn305.79bn16.17k54.18--32.674.2622.2522.25283.32--------4,444,876.00--11.95--15.3465.4759.178.4513.77--12.99--12.027.1113.72-46.6914.5129.3251.57
Biocon Ltd146.13bn12.00bn307.05bn3.41k25.58--10.182.1010.0310.03122.21--------42,877,050.00--4.31--5.9167.1761.3410.1910.87--1.66--8.4936.5422.03-28.644.4413.5024.57
GlaxoSmithKline Pharmaceuticals Limited33.11bn5.29bn318.45bn3.68k60.19--53.289.6231.2331.23195.53--------8,998,269.00--9.94--16.0160.3754.7115.9711.58--447.28--196.13-0.80252.3559.5811.62-35.7912.83
Data as of Mar 28 2024. Currency figures normalised to GlaxoSmithKline Pharmaceuticals Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

11.57%Per cent of shares held by top holders
HolderShares% Held
Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 20235.68m3.36%
Man Group Investments Ltd.as of 28 Feb 20232.48m1.46%
General Insurance Corp. of India (Invt Port)as of 30 Jun 20232.46m1.46%
Scottish Widows Ltd. (Investment Portfolio)as of 31 May 20211.94m1.15%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 29 Feb 20241.76m1.04%
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 29 Feb 20241.71m1.01%
The Vanguard Group, Inc.as of 07 Mar 20241.62m0.95%
Kotak Mahindra Asset Management Co. Ltd.as of 29 Feb 2024734.62k0.43%
BlackRock Investment Management (UK) Ltd.as of 29 Feb 2024634.94k0.38%
BlackRock Fund Advisorsas of 07 Mar 2024575.14k0.34%
More ▼
Data from 31 May 2021 - 21 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.